Why Viking Therapeutics Stock Plummeted by 24% in December

Yahoo Finance05:23

Viking Therapeutics Among Potential Buyout Candidates: Oppenheimer

Seeking AlphaJan 4 00:21

Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?

Yahoo FinanceJan 3 22:30

VKTX Stock Loses More Than 20% in Six Months: Should You Buy the Dip?

Zacks Jan 2 18:30

The competition is fierce! Musk once said that "Tirzepatide", which is more effective than semaglutide, will be launched in China. Who will dominate the weight loss drug market in 2025?

① Today, Eli Lilly and Co announced the official launch of tirzepatide in China, covering both type 2 diabetes and weight loss, and it is already available on some online platforms; ② Musk has claimed that tirzepatide is better than semaglutide, while the market is more focused on the pricing of tirzepatide and whether it will be included in medical insurance; ③ The competition in the GLP-1 sector will become even more intense in 2025, with Jiangsu Hengrui Pharmaceuticals, INNOVENT BIO, and Gan & Lee Pharmaceuticals receiving widespread attention.

cls.cnJan 2 16:20

Viking Therapeutics, Inc. (VKTX) Advances While Market Declines: Some Information for Investors

Yahoo FinanceJan 1 06:45